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a b s t r a c t
Unlike most other cell types, neurons preferentially metabolize glucose via the pentose phosphate
pathway (PPP) to maintain their antioxidant status. Inhibiting the PPP in neuronal cell models causes cell
death. In rodents, inhibition of this pathway causes selective dopaminergic cell death leading to motor
deficits resembling parkinsonism. Using postmortem human brain tissue, we characterized glucose
metabolism via the PPP in sporadic Parkinson’s disease (PD), Alzheimer’s disease (AD), and controls. AD
brains showed increased nicotinamide adenine dinucleotide phosphate (NADPH) production in areas
affected by disease. In PD however, increased NADPH production was only seen in the affected areas of
late-stage cases. Quantifying PPP NADPH-producing enzymes glucose-6-phosphate dehydrogenase and
6-phosphogluconate dehydrogenase by enzyme-linked immunosorbent assay, showed a reduction in the
putamen of early-stage PD and interestingly in the cerebellum of early and late-stage PD. Importantly,
there was no decrease in enzyme levels in the cortex, putamen, or cerebellum of AD. Our results suggest
that down-regulation of PPP enzymes and a failure to increase antioxidant reserve is an early event in the
pathogenesis of sporadic PD.
 2014 The Authors. Published by Elsevier Inc.
1. Introduction
Regeneration of oxidized glutathione by glutathione reductase
to its reduced form, glutathione (GSH) is vitally important in
combating oxidative stress in neurons. To reduce oxidized gluta-
thione, glutathione reductase uses nicotinamide adenine dinu-
cleotide phosphate (NADPH) as its cofactor. As levels of reactive
oxygen species accumulate in neurons, the demand for NADPH
increases (Ben-Yoseph et al., 1994). The levels of GSH in cells in
culture are directly related to the production of NADPH by the
pentose phosphate pathway (PPP) (Salvemini et al., 1999) and it
has been shown that the PPP is the primary source of NADPH in
cells (Pandolfi et al., 1995). Importantly, in neurons the rate
limiting glycolytic enzyme Phosphofructokinase B3 is translated
but subsequently ubiquitylated and degraded by the proteasome,
with the result that neurons preferentially metabolize glucose via
the PPP as opposed to glycolysis, in contrast to most other cell
types (Herrero-Mendez et al., 2009). Inhibiting glucose flux
through the PPP in these experiments was shown to cause
increased levels of oxidative stress and cell death, emphasizing the
extent to which neurons rely on the PPP for survival.
The effects of inhibiting the pentose phosphate and glutha-
thione pathways are similar to many of the pathologic changes
* Corresponding author at: Department of Molecular Neuroscience, Institute of
Neurology, London WC1N6BG, UK. Tel.: þ44 207 813 8321; fax: þ44 20 7829 8624.
E-mail address: laura.dunn11@uclmail.net (L. Dunn).
1 These authors contributed equally.
Contents lists available at ScienceDirect
Neurobiology of Aging
journal homepage: www.elsevier .com/locate/neuaging
0197-4580  2014 The Authors. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.neurobiolaging.2013.11.001
Neurobiology of Aging 35 (2014) 1111e1115
Open access under CC BY-NC-ND license.
Open access under CC BY-NC-ND license.
associated with Parkinson’s disease (PD). Depleting glutathione in
rats using L-buthionine sulfoximine, has been shown to cause
complex I and IV damage (Heales et al., 1995), a phenomenon,
which has been documented in postmortem PD brain tissue, with
complex I damage in PD widely reported (Schapira et al., 1989).
Similarly, decreased levels of total GSH have been measured in PD
brains (Perry et al., 1982; Sofic et al., 1992). This loss of GSH is found
in PD and Lewy body disorders, but not multiple system atrophy,
progressive supranuclear palsy, or Huntington’s disease (Sian et al.,
1994). One important, but less reported finding is that pharma-
cologic inhibition of the PPP in rats using the irreversible inhibitor
6-aminonicotinamide, has been shown to cause selective dopa-
minergic cell death in the striatum and muscle rigidity resembling
bradykinesia (Herken, 1990).
Recent studies investigating metabolism in PD have continued
to emphasize the importance of glucose usage in the disease
process, with glucose hypometabolism shown in PD using mag-
netic resonance imaging and fludeoxyglucose (18F) positron
emission tomography studies (Borghammer, 2012). Genetic
microarray studies of the substantia nigra in PD show a strong
association with the transcriptional regulator PGC1a, which is
involved in the control of glucose usage (Zheng et al., 2010) and in
animal models, knocking down a-synuclein (a-syn) has been
shown to cause increased glyoxylase-1 expression with accom-
panied glycation damage. A recent article-characterizing meta-
bolism in cultured adipocytes suggests that glucose uptake may be
regulated by a-syn signaling via the LPAR2/Gab1/PI3K/Akt
pathway (Rodriguez-Araujo et al., 2013). Importantly, studies
looking at the effect of glucagon-like-peptide 1 on animal models
of PD, have shown that modulating glucose metabolism is able to
reverse dopaminergic cell loss in rats (Harkavyi et al., 2008; Li
et al., 2009) and clinical trials of the glucagon-like-peptide 1
agonist exendin-4 are currently at stage II for use in PD (Tom Fol-
tyne, personal communication).
Through this study,we aim to characterize the activity of the PPP
in PD. Comparison of these results with those from AD and control
tissue; will allow any differences in NADPH production to be
identified. We hypothesize that reduced glucose metabolism via
the PPP in neurons, is an early event in sporadic PD pathogenesis.
2. Methods
2.1. Tissue
We studied flash-frozen tissue from the frontal cortex (Brod-
mann area 4), putamen, and cerebellar vermis. Cases with path-
ologically diagnosed PD were stratified according to the McKeith
criteria (McKeith et al., 2005). “Mild” cases were grouped ac-
cording to those with Lewy body pathology in the brain stem only
(McKeith brainstem predominant). “Moderate and/or severe”
cases were those with Lewy body pathology visible in the limbic
and neocortical areas (McKeith limbic and diffuse neocortical
Lewy body pathology). AD cases were similarly confirmed by
postmortem analysis and cases with Braak and Braak stages IV-VI
(Braak et al., 2003) were selected for these experiments. For each
brain region 13 controls, 11 mild PD, 12 moderate and/or severe,
and 13 AD cases were used. Where tissue was available, cortex,
putamen, and cerebellum samples were taken from the same
individual.
Age at death of all cases was 80  5 years. Controls were age
matched and showed no Lewy body pathology. Cases with Braak
and Braak stages II and under were used for this study.
Tissue was homogenized in an isolation buffer of 320 mM su-
crose, 1 mM ethylenediaminetetraacetic acid and 10 mM tris-base,
pH 7.4 using a mechanical homogenizer. Homogenates were
centrifuged for 15 minutes at 16,000 g at 4 C and the supernatant
removed for assaying. Samples were aliquoted into eppendorf tubes
and stored at 80 C before assay.
2.2. Assays
We characterized PPP in PD by assessing the total NADPH
generated by glucose-6-phosphate dehydrogenase (G6PD) and
6-phosphogluconate dehydrogenase (6PGD). This was done using
a modified protocol, based on that described by (Ninfali et al.,
1997). All readings were within the linear range.
Tissue homogenate was assayed under 2 separate conditions,
1 containing G6P and 6PG to calculate the total activity of the
pentose phosphate pathway and 1 with 6PG alone. G6PD activity
was calculated by subtracting the NADPH generated in the
combined condition, from that in the 6PG condition. Reaction
mixture contained a final concentration of 2 mM NADP, 1 mM
glucose-6-phosphate, and 1 mM phosphogluconic acid recon-
stituted in 1 M tris-HCl, 5 mM ethylenediaminetetraacetic acid
pH 7.6, 15% (vol/vol) WST-8 dye supplemented with 0.2 mM
1-methoxy phenazinium methylsulfate (All materials were pur-
chased from Sigma-Aldrich, Poole, UK). Samples were added to
the reaction mixture and incubated at 37 C for 15 minutes.
NADPH generated was calculated by measuring the increase in
absorbance at 450 nm.
2.3. Enzyme-linked immunosorbent assays (ELISAs)
The levels of the NADPH-producing enzymes G6PD and 6PGD
were calculated using ELISA kits specific for human G6PD and
6PGD, according to the manufacturer’s instructions (Wuhan life
sciences, Houston, TX, USA). Samples were run in duplicate.
2.4. Protein estimation
Protein concentration was estimated using the Bio-Rad DC
protein assay kit according to the manufacturer’s instructions (Bio-
Rad, Hemel Hempstead, UK).
2.5. Stastistical analyses
All results in this study were analyzed using a 1-way analysis of
variance (ANOVA) followed by a Bonferroni posttest. The signifi-
cance level was set at p < 0.05.
3. Results
We set out to characterize utilization of the PPP in flash frozen
postmortem PD brain tissue. To look at glucose metabolism via
this pathway over the course of disease progression, we identified
2 groups of PD samples, which were classified according to the
extent of their Lewy body pathology based on the McKeith Lewy
body pathology criteria (McKeith et al., 2005). Cases assigned to
Table 1
Postmortem delays for the samples used in this study. Flash-frozen tissue from the
frontal cortex, putamen, and cerebellum were used from each case
Group Postmortem delay
(mean in h  s.d)
Number of cases
Control 41.58  25.60 15
Mild PD 12.82  6.56 11
Moderate and/or
severe PD
49.32  18.65 16
AD 58.00  30.56 16
Key: AD, Alzheimer’s disease; PD, Parkinson’s disease; s.d, standard deviation.
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the “mild” group were those with Lewy body pathology pre-
dominantly in the brain stem. “Moderate and/or severe” cases
were those with Lewy body pathology that had progressed to the
limbic and neocortical areas. All cases in the “mild” group showed
a low level of Lewy body deposition in the putamen. AD cases were
confirmed by postmortem neuropathological examination and
cases with Braak and Braak stages IV-VI (Braak et al., 2003) were
used for these experiments. Controls were age matched and
confirmed to have Braak and Braak stages of II and under. Table 1
shows the postmortem delay for each group.
Total NADPH produced by the PPP was calculated by addition of
NADPH production by G6PD and 6PGD. To assess the impact of
enzyme expression on the production of NADPH, the levels of
G6PD and 6PGDwere alsomeasured by ELISA. Data for 6PGD ELISA
and enzyme activity levels are shown as Supplementary data.
3.1. Cortex
Increased NADPH production in the cortex has been shown to
occur in response to increased levels of oxidative stress in AD
(Martins et al., 1986). Calculation of NADPH production by the
PPP in our samples showed that generation of NADPH is signifi-
cantly increased in the AD and moderate and/or severe PD groups
as compared with controls (Fig. 1A gray bars, 1-way ANOVA fol-
lowed by Bonferroni posttest vs. control).
This increase was accompanied by higher levels of the rate-
limiting enzyme G6PD (Fig. 1B, gray bars, 1-way ANOVA fol-
lowed by Bonferroni posttest p < 0.05). In the mild PD group, that
is PD cases that do not have pathology in the cortex, there was no
increase in either the amount of NADPH produced or levels of
G6PD enzymes (Fig. 1A and B gray bars). Calculating the efficiency
of G6PD by expressing NADPH production per ELISA unit of G6PD
protein showed that there was no significant change in any of the
experimental groups characterized (Fig. 1C, gray bars, 1-way
ANOVA, p ¼ 0.8017).
3.2. Putamen
Next we looked at PPP usage in the putamen. Total NADPH
produced by the PPP in the putamen was significantly increased
in the brains of those with AD and in the moderate and/or severe
PD group (Fig. 1A, black bars, 1-way ANOVA followed by Bon-
ferroni posttest).
In AD, the levels of G6PD enzyme were not increased compared
with controls. Similarly the moderate and/or severe PD group
showed no significant increase in protein levels of the rate-
limiting enzyme G6PD however, the mild PD group showed a
significant decrease, suggesting a down-regulation of this
pathway at the protein level (Fig. 1B, black bars, 1-way ANOVA
followed by Bonferroni posttest). Calculating the efficiency of
G6PD for all samples, showed an activation of G6PD in the mild PD
and AD groups. In these groups, each ELISA unit of the enzyme
produced approximately twice as much NADPH per minute
compared with the control group (Fig. 1C, black bars, 1-way
ANOVA followed by Bonferroni posttest vs. control). Importantly,
AD cases with Braak and Braak stages IV-VI have amyloid beta and
Fig. 1. (A) Total nicotinamide adenine dinucleotide phosphate (NADPH) produced by
the pentose phosphate pathway. The combined activity of G6PD and 6PGD is shown.
One mU is defined as 1 mmole NADPH produced/min/unit of enzyme. Activity is shown
as the mean NADPH produced per unit expressed per mg total protein  SEM. (B) G6PD
enzyme levels. Levels of the G6PD enzyme were measured by enzyme-linked immu-
nosorbent assay (ELISA) and the combined total shown here per mg total protein. (C)
Efficiency of G6PD. The efficiency of G6PD was calculated by expressing the total
NADPH measured per mg total protein, per ELISA unit (U) of G6PD. Relative activities
are shown as mean NADPH produced per ELISA unit of protein  SEM. Levels are
shown as mean  SEM. Con- pathologically normal controls, n ¼ 13. Mild-McKeith
brainstem predominant Parkinson’s disease (PD) cases n ¼ 11. Mod/Sev-McKeith
limbic and diffuse neocortical cases. PD cases n ¼ 12. Alzheimer’s disease (AD) Braak
and Braak stages IV-VI n ¼ 13. Gray-cortex Brodmann area 4. Black-putamen. White-
cerebellar vermis. One-way analysis of variance (ANOVA) significance p < 0.05, with
Bonferroni posttest versus control * p < 0.05, ** p < 0.01, *** p < 0.001. Abbreviations:
AD, Alzheimer’s disease; ANOVA, analysis of variance; ELISA, enzyme-linked immu-
nosorbent assay; NADPH, nicotinamide adenine dinucleotide phosphate; PD, Parkin-
son’s disease; SEM, standard error of the mean.
L. Dunn et al. / Neurobiology of Aging 35 (2014) 1111e1115 1113
tau pathology in the putamen and the activation of G6PD in these
samples suggests that an oxidative stress response is occurring.
While both the mild and moderate and/or severe PD cases used
in this study showed Lewy body pathology in the putamen, it is only
the moderate and/or severe group which shows increased NADPH
production in response to this (Fig. 1A, black bars). This would
suggest that although the mild cases are able to match control
NADPH production levels, the ability to mount an oxidative stress
responsive is decreased and that an increase in NADPH is not seen
until PD pathology is more extensive.
3.3. Cerebellum
To assess the function of the PPP pathway in a region not
affected in PD, we measured NADPH production and the enzyme
levels of G6PD and 6PGD in the cerebellum.
NADPH production across all 3 experimental groups showed
no significant change in the cerebellum when compared with
controls (Fig. 1A, white bars, 1-way ANOVA p ¼ 0.8692). Inter-
estingly however, quantification of G6PD protein levels, again
showed a down-regulation of the rate-limiting enzyme that was
present in both PD groups, with enzyme levels showing a sig-
nificant decrease compared with control (Fig. 1B, white bars,
1-way ANOVA followed by Bonferroni posttest). Calculating the
efficiency of G6PD in these samples showed a 2-fold increase in
NADPH production of about 2-fold in these samples when
compared with controls (Fig. 1C, 1-way ANOVA followed by
Bonferroni posttest). As shown in the putamen of samples in the
mild PD group, despite a significant decrease in NADPH produc-
ing enzymes, net NADPH production in both PD groups remains
level with that of the controls, because of each unit of G6PD
producing more NADPH. Samples in the AD group showed no
difference in the NADPH produced (Fig. 1A, white bars), or in the
levels of PPP enzymes measured (Fig. 1B, white bars).
4. Discussion
Neurons are subjected to high levels of oxidative stress because
of a relatively high level of oxidative phosphorylation and nitric
oxide signaling from astrocytes (Bolanos and Heales, 2010.),
leaving them vulnerable to damage. It has been shown that pro-
duction of NADPH from the PPP is responsible for reduction of
oxidative species and therefore reducing levels of oxidative stress,
leaving neurons able to function normally. Inhibition of the PPP is
deleterious to neurons (Filosa et al., 2003; Pandolfi et al., 1995).
Increased levels of oxidative stress are important in the patho-
genesis of PD (Alam et al., 1997; Dexter et al., 1989; Floor et al.,
1998) and it has been suggested that oxidative stress could play
an important role in the formation of Lewy body pathology
(Jenner and Olanow, 1996). As the PPP is the main source of de-
fense against oxidative stress in neurons, we thought it important
to characterize the usage of this pathway in PD. Studies showing
increased activity of the PPP in AD (Martins et al., 1986), neuro-
muscular diseases (Meijer, 1991), myocardial infarction (Gupte,
2008), and studies using hepatocyte cell models (Ursini et al.,
1997) support the idea that oxidative stress is normally met
with increased production of NADPH. However, characterization
of the PPP in our experiments has shown that NADPH production
is not increased in the putamen of samples with early stage PD and
furthermore, PPP enzyme levels are actually decreased. This is
despite widely documented evidence that dopaminergic cell
death in the striatum of PD cases is accompanied by increased
markers for oxidative stress and neuroinflammation in postmor-
tem samples (Alam et al., 1997; Imamura et al., 2003; Marttila
et al., 1988; Ouchi et al., 2005; Sanchez-Ramos et al., 1994) and
in vivo, by positron emission tomography imaging studies (Ikawa
et al., 2011). Similarly, although there are a number of published
studies showing increased levels of oxidative stress in the frontal
cortex of cases with both clinical and preclinical PD (Dalfo et al.,
2005; Ferrer, 2009; Parker et al., 2008), the early stage cases in
our experiments again did not show an increase in NADPH levels.
This could be because of faulty oxidative stress-sensing mecha-
nisms in affected neurons, or because of an active suppression
mechanism that is stopping increased NADPH production from
occurring.
An article looking at the PPP in ALS, showed that
neuroblastoma-spinal cord hybrid cell lines (NSC34) carrying
G93A or G37R SOD1 mutations display decreased levels of G6PD
enzyme, which affects the production of NADPH by this pathway
(Kirby et al., 2005). Similarly ataxia telangiectasia mutated
knockout mice also show a reduction of G6PD in the cerebellum
(Cosentino et al., 2011), suggesting that downregulation of the PPP
in disease could be a key mechanism in some forms of neuro-
degeneration. Taking our results together with data from cell and
animal models, suggests that dysregulation of the PPP could be
causing oxidative stress because of less efficient GSH recycling
(Heales et al., 1995; Herrero-Mendez et al., 2009) and that dys-
regulation of the PPP could be causative factor in the increased
levels of oxidative stress seen in PD.
The results of our experiments suggest that there are 2 stages of
PPP involvement with oxidative stress in PD. In the early stages of
disease, lower levels of PPP enzymes in the putamen could be
causing increased levels of oxidative stress. In response to this,
G6PD is activated, potentially by posttranslational modification of
the enzyme as shown in other studies (Cosentino et al., 2011;
Ursini et al., 1997) and the increased demand for NADPH met by
increased activity per ELISA unit of the protein. In the later stages
of disease, where pathology has spread to the limbic system
and neocortex, our results show that there is a switch from
activation of G6PD at its existing levels, to upregulating the
NADPH-producing enzymes at a protein level. Interestingly, the
exact mechanisms for regulation seem to differ between brain
regions and despite evidence of increased oxidative stress in the
cerebellum in PD, the cerebellum does not show evidence of
neurodegeneration. Elucidating the mechanisms underlying these
differences could be important in understanding the vulnerability
of certain cell types over others in different neurodegenerative
diseases. The results of this study come with the caveat that the
tissue was from postmortem brains and therefore only provides a
snapshot of the changes occurring at that time. Despite this,
further investigation into mechanisms that are potentially un-
derlying our findings may prove important in understanding the
pathogenesis of PD.
As discussed, the evidence for perturbed glucose metabolism in
PD is increasing. The results of this study shed light on a potentially
new mechanism in the pathogenesis of sporadic PD and when
takenwith further studies from cell and animal models, may lead to
better understanding of these mechanisms. Our data suggest that
down-regulation of the PPP in PD could be a primary event in
disease progression and further research down this avenue may
provide potential targets for future therapeutic avenues.
We hypothesize that mitochondrial damage in PD occurs as a
direct result of PPP dysregulation and that a-syn plays an important
role in the altered metabolism of glucose via the PPP in this disease.
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